Print friendly
E-mail story
Contact an Editor
iPod friendly
Comments
Bookmark This
del.icio.us.
Digg!
furl
google
newsvine
reddit
technorati
Facebook
Yahoo!In recent years, infectious diseases has jumped from the animal kingdom onto human terrain with higher prevalence and lethal consequences, prompting the science world to investigate causes for this terrible outbreak. Emerging infectious diseases are those which occur in new populations or places, are reintroduced or newly introduced, or become highly virulent or resistant to certain treatments. Typically, emerging infectious diseases arise for multiple reasons, spanning from deforestation to human behavior, and entail certain harm for their host species, or the species which contains the infectious pathogen.
Jonathan Davies, a scientist at UCSB’s National Center for Ecological Analysis and Synthesis (NCEAS) and Amy Pederson, a research fellow at the University of Sheffield addressed the growing risk of emerging infectious disease in an analysis showing how both the proximity and similarities between species can determine the communicability of a pathogen between various hosts. “Infectious diseases crossing species barriers pose a huge and increasing threat to human health and the conservation of wild species,” said Davies. “The critical question we investigated is what determines the breadth of host species that a pathogen can infect.”
Published in this week’s Proceedings of the Royal Society B, the team’s research explains that “host shifts” from animal reservoirs to humans typically occur between closely related species with similar biological make-ups and immune responses. Such was the case with Simian Immunodeficiency Virus (SIV) in primates which crossed over to humans as Human Immunodeficiency Virus (HIV), theoretically during the preparation of chimpanzee meat, or “bush meat.”
However, Davies and Pederson said pathogens traverse genetic borders with astounding ease, suggesting that location rather than genetics plays a greater role in host shifts. “Viruses are more adept at jumping between distantly related host species, so that geographical proximity rather than evolutionary relatedness determines the spread of viral diseases,” said Davies.
Viral disease like Bird Flu, West Nile Virus, and Hendra Virus, which affect birds and bats, respectively, now affect humans and — as Pederson predicts — may only be the tip of the iceberg. Because of urban expansion, humans are more exposed to wild animals and their pathogens.
“We suggest hotspots of future emerging diseases may be found where humans come into close proximity with wild primates, as is increasingly the case in the forests of Central and West Africa due to rapidly growing human populations and scarcity of resources in this region,” said Pederson. “In addition, we are likely to see an increase in outbreaks of novel viral diseases as humans invade previously isolated habitats, and these may be just as likely to jump from a rat or a bat, as an ape.”
Fortunately, the ability to predict host shifts can help limit the incidence of outbreaks and/or minimize the resulting mortality, morbidity and financial expenses.
Double-clicking on any word or phrase in this story will open a reference window with definitions and links to other reference material.
Previous Month
Comments
Discussion Guidelines
My biotech company has had encouraging results treating West Nile virus encephalitis since 2003: 81% treatment success rate in people (22 of 27), 75% in horses (6 of 8), and 50% in birds (6 of 12).
Our approach works best when people first have symptoms of a fever and headache. But we’ve been able to help people even a few years after the initial episode of WNV encephalitis.
Our first 8 WNV patients were published in a peer-reviewed medical journal in 2004 (1). We’re eager to see if our approach works again this year.
The drugs we use are already approved by the FDA for blood pressure. They seem to be anti-inflammatory, too. People with a normal immune system who get sick from the West Nile virus appear to overdo their immune response to the virus. Our approach is meant to gently calm down their exaggerated immune response, the so-called “cytokine storm.” It can be used in the very old, the very young, and everybody in between.
It can also be used for almost any virus except the herpes viruses, which is why our approach was included in the BioShield II Act of April 28, 2005, co-sponsored by Senators Lieberman, Hatch, and Brownback. The bill was never debated, but our approach was mentioned in Section 2151 (http://www.govtrack.us/congress/billtext...). In 2004, I briefed the White House and the Dept of Homeland Security about it. The UN is aware of our approach in the context of bird flu, although they haven’t tested it, preferring to push Roche’s drug Tamiflu instead.
The drugs we use cost about $1 a tablet. We use one or two pills a day. They’re carried in every drugstore on earth. You have to admit, if it works, that this would be a pretty sweet deal for public health!
Anybody who wants to download our WNV trial protocol can do so for free at any time by clicking on the "West Nile trial" link on our company’s homepage at www.genomed.com.
Reference
1: Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 (For PDF file, click on paper #6 at: http://www.genomed.com/index.cfm?action=...) -- see Table 2 for WNV patients
Sincerely,
Dave Moskowitz MD FACP
CEO, GenoMed, Inc.
www.genomed.com
“The public health company™”
Ticker symbol: GMED (on the Pink Sheets)
DrMoskowitz (anonymous profile)
May 3, 2008 at 8:19 a.m. (Suggest removal)
Post a comment